Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer.
Zhonghan ZhangYang ZhangFan LuoYuxiang MaWenfeng FangJing ZhanSu LiYunpeng YangYuanyuan ZhaoShaodong HongTing ZhouYaxiong ZhangShen ZhaoYan HuangHongyun ZhaoLi ZhangPublished in: Clinical and translational medicine (2020)
Clinicaltrials.gov, NCT02824458, date of registration June 23, 2016.